The MAPLE-HCM trial shows aficamten improves exercise capacity and symptoms more than metoprolol in symptomatic obstructive hypertrophic cardiomyopathy. The post ESC 2025: First-Line Potential for Aficamten in Obstructive Cardiomyopathy appeared first on European Medical Journal.
